Health Care · Biological Products, (No Diagnostic Substances)

REPL Replimune Group, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1737953112 filings
Russell 2000

REPL at a glance

Replimune Group, Inc. (REPL, SEC CIK 1737953) filed its latest 10-K annual report on June 29, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on October 28, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Replimune Group, Inc. (REPL) shares worth $426.7 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Hill Emily Luisa on November 16, 2026 of 14,709 shares at $21.60 per share.
  • In the last 90 days, REPL insiders reported 0 open-market purchases ($0) and 6 open-market sales ($2.3M) on Form 4, a net sale of $2.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 6 sells
Net −$2.3M
13F holders
25 funds
$426.7M · −2 vs prior quarter
Latest 8-K
Oct 28, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Mar 31, 2026

Full analysis →

Management Discussion & Analysis

  • No product revenue, net loss $313.9M in 2026 vs $247.3M in 2025, operating expenses $319.9M vs $261.6M, loss from operations increased by $58.3M
  • R&D expense $221.2M (+17%) driven by $59.8M RP1 and $26.0M RP2 costs; SG&A $98.7M (+37%), personnel costs main driver
  • Best segment RP2 with $25.95M costs (up $13.9M); worst RP3 down $2.3M to $2.67M; RP1 increased $12.9M driven by IGNYTE-3 study
  • Cash and investments $268.9M as of March 31, 2026; net cash used in operations $280.3M; financing activities provided $66.3M including $35.0M debt; capex approx. $4.2M
  • Management expects operating losses into 2027; cash runway into Q1 2027; plans depend on FDA approval outcome for RP1; risks include need for additional financing and potential restructuring

Business Overview

  • Clinical-stage biotech focused on oncolytic immunotherapy using engineered HSV-1 platform (RPx) to maximally activate systemic anti-tumor immune response
  • FDA issued second Complete Response Letter for RP1 BLA in advanced melanoma; ongoing FDA collaboration and expedited Class 1 resubmission action date August 2, 2026
  • Expanded pivotal RP1 development with Phase 3 IGNYTE-3 trial enrolling anti-PD-1 failed melanoma patients; complex FDA feedback on control arms and trial design
  • Workforce reduced ~55% in April 2026 restructuring; 465 employees as of March 31, 2026, with 75% in R&D, reflecting operational scale-back risks
  • RP2 advanced in metastatic uveal melanoma (mUM) with Phase 2/3 REVEAL trial targeting immune checkpoint inhibitor-naïve patients; additional signal-finding in liver cancers with Roche collaboration

Risk Factors

  • Regulatory risk FDA Biologics License Application for RP1: two CRLs issued (July 2025, April 2026), with FDA advisory committee meeting scheduled July 2026
  • Geopolitical threat Russia-Ukraine and Israel-Hamas conflicts causing potential supply chain disruptions and inflationary impacts on business
  • Operational risk reliance on BMS, Roche for anti-PD-1 therapies (nivolumab, atezolizumab/bevacizumab) critical for combination trials and commercialization
  • Competitive risk market competition with Amgen's T-Vec oncolytic immunotherapy and others with greater resources and faster development
  • Financial risk net loss $313.9M FY 2026, accumulated deficit $1.26B, cash runway into Q1 2027 without additional financing

AI summary of the REPL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY, with no product sales before TUDRIQEV commercialization in early October 2026
  • Operating margin not meaningful: operating loss $56.3M vs $84.3M YoY, net loss $57.1M vs $83.1M
  • Best program RP2: R&D spending $9.4M, up $4.2M YoY; worst RP1: $8.6M, down $9.0M
  • Operating cash outflow $123.4M; cash and equivalents plus short-term investments $307.8M at September 30, 2026
  • Outlook: cash sufficient for greater than twelve months; continued losses, commercialization and confirmatory-trial costs expectedETwitter

Risk Factors

  • New commercialization risk triggered by August 2026 FDA approval: rebuilding sales capabilities after significant reductions in force may delay TUDRIQEV launch
  • Most material regulatory update: accelerated approval depends on IGNYTE-3 confirmation, with FDA withdrawal possible if clinical benefit is unverified
  • Near-term market risk: TUDRIQEV remains the sole approved product, making revenue dependent on U.S. adoption in its melanoma indication
  • Financial risk: $307.8 million cash at September 30, 2026, but additional financing remains necessary and may be unavailable on acceptable terms
  • Manufacturing risk: approximately 63,000-square-foot Framingham facility may incur higher-than-expected costs or fail to achieve anticipated operating efficiencies

AI summary of the REPL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Fiscal Q2 2027 launch underway: TUDRIQEV delivered October 6, with more than 15 institutions prescribing
  • Commercial traction: Replimune engaged over 70% of its initial 200 priority accounts, with formulary placements emerging

Item 2.02: Results of Operations and Financial Condition

  • Q2 fiscal 2026 results for quarter ended September 30, 2026 announced October 28, 2026
  • Corporate updates included alongside financial results
Filed Sep 16, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • PwC ratified as independent auditor for fiscal year ending March 31, 2027, with 63,434,745 votes in favor
  • Executive compensation approved advisory basis, with 48,641,528 votes for and 14,440,328 broker non-votes

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • Common-stock authorization doubled from 150 million to 300 million shares
  • Stockholders approved the amendment at the September 15, 2026 annual meeting
Filed Aug 14, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • FDA accelerated approval makes TUDRIQEV Replimune’s first commercial product; U.S. launch expected within 60 days
  • Approval covers advanced cutaneous melanoma after PD-1 progression, creating near-term commercial revenue potential

Item 2.02: Results of Operations and Financial Condition

  • Q1 fiscal 2026 results for quarter ended June 30, 2026 announced by Replimune
  • Corporate updates included alongside quarterly financial results

AI summaries of REPL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for REPL

Don't miss the next REPL filing

  • Alerts as it files. A push when REPL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut REPL, by share count.
  • Ask anything. An AI agent that reads every REPL filing and answers with sources.

REPL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Hill Emily LuisaSellNov 16, 2026$21.60
Patel SushilSellNov 16, 2026$21.60
Xynos KonstantinosSellNov 16, 2026$21.60
Schwendenman AndrewSellNov 16, 2026$21.60
SLATTERY JOSEPH PSellNov 9, 2026$21.80
Dhingra KapilMNov 2, 2026$1.75
Dhingra KapilMNov 2, 2026-
Dhingra KapilSellNov 2, 2026$19.00

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Operating Income-$234.8M-$261.6M-$319.9M
Net Income-$215.8M-$247.3M-$313.9M
Balance Sheet
Total Assets$487.7M$551.3M$332.4M
Equity$374.5M$415.8M$166.2M
ROE-57.6%-59.5%-188.9%
Per Share
EPS$-3.24$-3.07$-3.38
Cash Flow
Operating CF-$185.5M-$192.3M-$280.3M

Source: XBRL data in Replimune Group, Inc. (REPL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate REPL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
REPL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$426.7M
Q2 202627$373.7M
Q1 202628$258.0M
Q4 202524$339.9M
Q3 202524$127.5M
Q2 202525$283.0M
Q1 202521$131.2M
Q4 202417$128.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 191 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

REPL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 10, 2026--
4Nov 3, 2026--
8-KOct 28, 2026Analysis-
10-QOct 28, 2026Analysis
8-KSep 16, 2026Analysis-
4Aug 24, 2026--
4Aug 19, 2026--
8-KAug 14, 2026Analysis-
10-QAug 14, 2026Analysis
4Aug 12, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
4Aug 11, 2026--
8-KAug 11, 2026Analysis-
8-KAug 10, 2026Analysis-
SC 13GAug 10, 2026-
SC 13GAug 7, 2026-
8-KAug 7, 2026Analysis-
8-KJul 31, 2026Analysis-
8-KJul 30, 2026Analysis-

Related Health Care companies

All Health Care →

REPL SEC filings: frequently asked questions

Are REPL insiders buying or selling?

In the last 90 days, Replimune Group, Inc. (REPL) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $2.3 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold REPL stock?

As of September 30, 2026, the largest Replimune Group, Inc. (REPL) holders among the 13F filers tracked by SignalX were BlackRock ($116.5 million), State Street Corp ($55.3 million), Vanguard Capital Management LLC ($45.0 million), Goldman Sachs Group ($44.0 million), AQR Capital Management ($30.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What are the main risks in REPL's latest 10-K?

In the 10-K filed June 29, 2026, Replimune Group, Inc. (REPL) flagged: Regulatory risk FDA Biologics License Application for RP1: two CRLs issued (July 2025, April 2026), with FDA advisory committee meeting scheduled July 2026. Geopolitical threat Russia-Ukraine and Israel-Hamas conflicts causing potential supply chain disruptions and inflationary impacts on business. (AI summary of the Risk Factors section.)

What did REPL report in its latest 8-K?

Replimune Group, Inc. (REPL) filed an 8-K on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal Q2 2027 launch underway: TUDRIQEV delivered October 6, with more than 15 institutions prescribing.

What are the latest REPL SEC filings?

Replimune Group, Inc. (REPL) filed its latest 10-K annual report on June 29, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on October 28, 2026 and a Form 4 insider filing on November 18, 2026.

What is REPL's SEC CIK number?

Replimune Group, Inc. (REPL)'s SEC Central Index Key (CIK) is 1737953. EDGAR lists every REPL filing under that number.

Ask anything about REPL

The research agent reads REPL's filings, financials, insider trades and 13F holders, then answers with sources.